Search for a reference number
Dear Freedom of Information Team
Please could I request, under the Freedom of Information Act 2000.
1. The total number of stroke patients in the Trust and the number of stroke patients in the Trust that were:
a) offered a six-month post-stroke review
and
b) had a six-month post-stroke review for each of the past 5 years, beginning with 2020.
I look forward to your reply in the statutory 20 days.
I would appreciate a reference number being provided so I can keep track of the request.
Under the Freedom of Information Act 2000 I would like to request the following information.
Please provide two sets of waiting list data on paediatric elective care (RTT) (patients aged 0–17) for your Trust, disaggregated by:
1. Ethnicity (using NHS standard ethnicity categories), and
2. Indices of Multiple Deprivation (IMD) deciles or quintiles (based on patient postcode or other available proxy).
For each combination of ethnicity and IMD group, please provide the number of patients waiting in each of the following time bands:
1. Up to 18 weeks
2. 18 to 26 weeks
3. 26 to 40 weeks
4. 40 to 52 weeks
5. 52 weeks and over
Please provide this data monthly, from September 2021 to September 2025 (or the most recent available month), with each month reported separately.
If providing both ethnicity and IMD breakdowns would exceed the cost, please prioritise the ethnicity breakdown.
Please provide the data in spreadsheet format (e.g., Excel or CSV).
1. Please provide Hemophilia A patient numbers broken down by: age, disease severity and treatment regimen (PPx denotes use for prophylaxis and OD denotes use on demand). I have proposed a format below to capture the relevant information. If data is not available by age breakdown, then please provide aggregated total in the yellow highlighted column:
July through September 2025 Age
Brand name (scientific) 0-12 years 13+
Mild Moderate Severe Mild Moderate Severe
PPx OD PPx OD PPx OD PPx OD PPx OD PPx OD
Hemlibra (emicizumab)
Altuvoct (giroctocogene fitelparvovec)
Esperoct (turoctocog alfa pegol)
Elocta (efmoroctocog alfa)
Advate (octocog alfa)
Kovaltry (octocog alfa)
Iblias (octocog alfa)
Refacto AF (moroctocog alfa)
Xyntha (moroctocog alfa)
NovoEight (turoctocog alfa)
Nuwiq (simoctocog alfa)
Vihuma (simoctocog alfa)
Inhibitor patients
2. For Hemlibra-treated Hemophilia A Inhibitor patients, please indicate the number of patients by age group and dosing frequency for Q3’25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total:
Age group (Hemophilia A inhibitor patients) Once weekly Every 2 weeks Every 4 weeks
0-12 years
13+ years
Total
Non-inhibitor patients
3. For Hemlibra-treated Hemophilia A non-inhibitor patients, please indicate the number of patients by age group and dosing frequency for Q3’25 (July–September 2025). If data is not available by age breakdown then please provide aggregated total:
Age group (Hemophilia A non-inhibitor patients) Once weekly Every 2 weeks Every 4 weeks
0-12 years
13+ years
Total
Total number of patients that have been referred to or visited your trust for treatment where they have been assessed as meeting the diagnostic criteria for Binge Eating Disorder (BED) (e.g. ICD-10 code F50.81 or equivalent)
2020
2021
2022
2023
2024
2025
Subject: Freedom of Information Request – Non-Pharmacological ADHD Interventions for Children
Dear FOI Officer,
I am writing to request information under the Freedom of Information Act 2000 regarding the provision of non-pharmacological interventions for children and young people with Attention Deficit Hyperactivity Disorder (ADHD) within your Trust. To help me understand your service model, I would be grateful if you could provide responses to the following:
1. Service Provision
• – Do you provide non-pharmacological interventions for children and young people diagnosed with ADHD?
• – If so, please list the types of interventions offered (e.g., parent training, CBT, psychoeducation, skills groups, school liaison, peer support, digital interventions, etc.).
• – Are these delivered by your Trust directly, jointly with external providers, or commissioned from other organisations?
• With what frequency are patients/families offered these sessions?
• How many sessions are offered to patients/families or at what point is intervention ceased?
2. Referral & Access
• – At what stage of the care pathway are non-pharmacological interventions offered (e.g., pre-diagnosis, post-diagnosis, alongside medication, instead of medication)?
• – What are the eligibility criteria (if any) for accessing these interventions?
3. Workforce & Delivery
• – Which professional groups deliver these interventions (e.g., psychologists, nurses, occupational therapists, social workers, peer support workers)?
How many WTE (whole time equivalent) staff are currently employed in delivering ADHD-related non-pharmacological interventions?
4. Capacity & Outcomes
• – Approximately how many children/young people accessed these interventions in the last financial year (April–March)?
• – Do you collect outcome measures for these interventions? If yes, please specify which tools or measures are used (e.g., SDQ, SNAP-IV, goal-based outcomes, parent/carer feedback, etc.).
5. Commissioning & Funding
• – Are these interventions funded within core CAMHS/neurodevelopmental services, or separately commissioned?
• – Has your Trust secured any additional funding streams (e.g., NHS Long Term Plan, local authority joint commissioning) to support delivery?
6. Future Planning
• – Are there plans to expand, reduce, or change the provision of non-pharmacological ADHD interventions for children in the next 2 years?
Notes
– Please provide the information in electronic format (Word, Excel, or PDF).
– If the information requested exceeds the cost/time limit, please advise which elements could be prioritised.
– If you do not hold the information, please confirm whether another organisation may be responsible.
Thank you for your assistance. I look forward to your response within the statutory 20 working days.
The lifetime prevalence of mental disorder in the general population is 1 in 4. For profoundly deaf people this approaches 1 in 2 yet the number of deaf adults accessing mental health services is very low.
The National Deaf Mental Health Service supports Deaf BSL users across the middle third of England.
We have seen a fall in referrals for community and inpatients in recent years.
We are keen to know if there are people accessing local services who may not have been considered for referral to specialised services.
I would be grateful if you could provide the number of adult deaf sign language users who are have been inpatients within your Trust over the last 5 years.
Please could you provide the number of adult Deaf sign language users currently on the community caseload of the Trust.
Please provide the number of adult Deaf sign language users supported by the trust community services in the last 5 years.
Dear Sir/Madam,
This is a Freedom of Information Act request. I would like to know the following information:
• How many children (under 18s) have been given the contraceptive implant for each of the last five calendar years (2021, 2022, 2023, 2024 and 2025 so far)?
• Please provide a breakdown by age of all children given the contraceptive implant for each of the last five calendar years (2021, 2022, 2023, 2024 and 2025 so far).
• Please consider all ages from the youngest person given the implant up to and including those given the implant aged 17. For the answer to this question, a table like this may help illustrate the information I am asking for:
•
Age 9 10 11 12 13 14 etc up to 17
2021
2022
2023
2024
2025 so far
I look forward to a response within 20 working days. Please contact me on this email address if you have any queries.
Dear FOI Officer,
I am writing to request information under the Freedom of Information Act 2000.
Please could you provide the following information:
1. 1. The total number of recorded incidents of slips, trips, and falls in home bathrooms involving patients within your Trust/Health Board for each calendar year from 2020 to September 2025.
2. 2.If available, a breakdown of these figures by:
a. Age groups (50–59, 60–69, 70–79, 80–99, 100+)
b. Gender (Male, Female)
If any part of this request is unclear or would exceed the cost limit, please provide advice and assistance as required by Section 16 of the FOI Act.
I look forward to your response within the statutory 20 working days.
Please provide the data in an electronic format if possible.
Best wishes,
Under the Freedom of Information Act 2000, I would like to request the following information:
1. The current average waiting time for patients to access your mental health services.
2. The total number of patients currently on waiting lists for mental health services.
Please provide the most recent figures you hold (as of September 2025), ideally in spreadsheet format (Excel/CSV).
Dear the Gloucestershire Health and Care NHS Foundation Trust,
I hope you are well.
I’m a reporter for the Colchester Gazette and Newsquest.
I am writing to request information under the Freedom of Information Act 2000. I would like to obtain the following information:
• The number of miscarried babies that were reported as discarded, lost, or contaminated in the Gloucestershire Health and Care NHS Foundation Trust for the past five years.
• A breakdown of these incidents by year
• A breakdown of any costs due to these incidents
• A breakdown of hours spent by NHS workers either attempting to find or reporting or spending time on these incidents
This FOI follows this article https://www.gazette-news.co.uk/news/25393764.essex-womans-miscarried-baby-lost-hospital-contaminated/.
Please provide this information in an electronic format. If this request is too broad or unclear, I would be grateful if you could contact me to provide advice and assistance on how to refine it.
I am also contacting other NHS trusts across the United Kingdom.
Thank you for your time and assistance.
Dear Gloucestershire Health and Care NHS Foundation Trust,
I am writing to request the following information under the Freedom of Information Act.
The total number of Respiratory Physiology – Sleep Studies (10) performed in each of the respective financial years 2019/20, 2020/21, 2021/22, 2022/23, and 2023/24.
If the full dataset is not available, please supply the information you hold and advise how I might obtain the remainder.
We’re looking to conduct FOI requests with NHS trusts regarding prescriptions issued for sleep medications in the UK. For example, how many prescriptions were issued for sleep medications (e.g. Zopiclone, melatonin) in the last 5 years
• Total number of sleep disorders recorded in the last five years (broken down by year) and split by age range – I have attached a spreadsheet with the full list.
• The total number of drug prescriptions issued for the following sleep disorders in the past five years (broken down by year and by drug type e.g. Melatonin, Benzodiazepines, Z-drugs)
• The total number of patients referred to non-drug treatments, such as CBT-I
Please could you provide the following information: General Information
1. The total number of radiology scans performed at NHS hospitals in the last 12 months, broken down by modality (CT, MRI, and nuclear medicine scans).
2. A detailed breakdown of the scans performed by body part for each of the above modalities (For example CT head, MRI Spine, bone scan etc) at each trust.
3. The total number of outsourced scans for reporting purposes, categorized by modality (CT, MRI, and nuclear medicine) for each hospital / trust. Outsourcing and Teleradiology
4. Whether any radiology scans are outsourced to external providers by the hospitals.
5. The percentage of scans outsourced for each modality, if applicable at each hospital.
6. The names of the external providers contracted for outsourced radiology reporting to each NSH hospital.
7. The cost per scan for outsourced services, broken down by modality and body part. Financial Information
8. The total expenditure on outsourced radiology reporting services in the last financial year per trust.
9. Whether there are fixed pricing agreements between teleradiology providers and the hospitals, and if so, the details of these agreements to include start and finish dates and the cost in pounds. Contracts and Agreements
10. Any active contracts the hospitals have with teleradiology companies, including: a. The names of the contracted providers. b. The start and end dates of the contracts. c. The performance or quality metrics outlined in the contracts. Backlogs and Reporting Times
11. The current backlog for radiology scan reporting, broken down by modality and body part at each NHS trust.
12. The average reporting time for in-house radiology scans, categorized by modality.
13. The average reporting time for outsourced scans.
14. Whether specific modalities or body parts have more significant backlogs. Additional Details
15. Any delays in reporting radiology scans over the last 12 months and the primary causes of such delays.
16. Whether the hospital has plans to reduce reliance on outsourcing for radiology reporting, and if so, the details of these strategies.
Dear Sir/Madam,
I am writing under the Freedom of Information Act to make a request for information on the use of electroconvulsive therapy (ECT).
The information being requested is as follows:
1. Please provide the number of ECT treatments given to patients in the year 2025 to date (with the date range this applies to)
2. Please provide the number of patients having received ECT treatment in the year 2025 to date (with the date range this applies to)
I look forward to hearing from you in due course.
Good afternoon,
After extensive research, we have been unable to find the following data, and I would now like to request it from you.
Please can I request the number of CT scans referred from primary care for SCITID 12295008 Bronchiectasis, and if you have open access to CT scans from primary care.
Best wishes,
Dear NHS Trust officers,
I’m writing to request some information under the Freedom of Information Act.
For each month in the past 2 years (Aug 2023 – Aug 2025), please let me know:
1) the Number of people’s bodies that were moved between hospitals’ mortuaries
2) the Median and Maximum number of days for a body to be released from a hospital mortuary to a funeral director
Please provide such data electronically, ideally as a spreadsheet.
To whom it may concern, I am writing to you under the Freedom of Information Act 2000 on behalf of Myeloma UK to request the following information: 1. Is your health trust currently treating myeloma patients 2. Please list the hospitals in your board/trust that are currently treating myeloma patients. 3. Please list how many myeloma patients are being treated by your board/trust. Please break this down by hospital. 4. Is your health trust currently treating myeloma patients with elranatamab or teclistamab. Please break this down by hospital. 5. Please list how many people have been given a) elranatamab or b) teclistamab since approval by the National Institute of Health and Care Excellence in 2024 (TA1023 and TA1015. If possible, please break this down by hospital. 6. Do you have a service level agreement or referral system in place with any other health trusts to deliver a) elranatamab or b) teclistamab to patients. If the answer this question is yes, which health boards / trusts do you have an agreement in place with. If you have any queries, please don’t hesitate to contact me via e-mail. Thank you for your time and I look forward to your response.
I keen to understand how much use the Acute Trust specialists are able to make of the Outpatient clinic facilities in Gloucestershire’s Community Hospitals. I am particularly interested in to know what Acute Trust services are provided at Moreton Community Hospital, although the question is also relevant to all of Gloucestershire’s Community Hospitals.
I believe that prior to the Pandemic good use of Moreton’s clinic space by Acute Trust Consultants etc was made, but that now clinics are few and far between – physio, orthoptists, hearing aid support. Your website suggests that clinics are held in response to demand. What constitutes “demand”?
Given the Secretary of State’s wish to move more specialist provision into the community, it would be helpful to know to what extent that already happens in our Community Hospitals, and what are the issues that prevent greater use. I guess that cost is a major block to greater use – but who bears what cost (GHC? GHT? ICB?)
As background, I am a retired GP and am currently a Public Governor at Gloucestershire Hospitals Trust. This issue has recently been raised with me by PPG members from North Cotswolds GP Practices. Residents in that area have long journey times to and from GRH or CGH, and are increasingly frustrated that OP clinics appear not to be held in the excellent facility at Moreton and elsewhere. I have family living in North Cotswolds too and understand their frustrations.
Would it be possible to provide me with a timetable of current use of Moreton clinic space, or would that need to go through FOI channels?
Please provide the following information, broken down by month, between January 2020 and July 2025 inclusive. If this is not possible, please instead provide it broken down by calendar year, 2020 to 2025 inclusive.
1. The number of times a patient was admitted where exposure to air pollution (International Classification of Diseases, tenth revision (ICD-10) code Z581)* was recorded as a contributing factor to the admission.
(* I understand this is the code used by NHS trusts to log exposure to air pollution, but if your trust uses a different code or some other system, please still provide the relevant data)
1a. If possible, please tell me what the primary diagnosis was for each of these admissions.
(For clarity, I want to know total numbers admitted with each primary diagnosis — for example, if 45 people were admitted with a primary diagnosis of asthma where exposure to air pollution was identified as a contributing factor.)
2. Please tell me how many of the patients in question 1 subsequently died in hospital.
If it is not possible to provide the information requested due to the information exceeding the cost of compliance limits identified in Section 12, please provide advice and assistance, under the Section 16 obligations of the Act, as to how I can refine my request.
If you can identify any ways that my request could be refined I would be grateful for any further advice and assistance.
If you are able to supply some of this information more quickly than other items, please supply each item when you can rather than delay everything until it is all available.
I’d like to make the following request under the freedom of information act.
Could you tell me, for 2019-2025
a) how many patients were transferred out-of-area
b) the furthest distance a patient was transferred
c) the longest period a patient was placed in an out-of-area trust
Dear colleagues,
We are undertaking a survey regarding the management pathway of elderly patients (>65 years old) presenting with trauma in the Emergency Department.
I am emailing you to a make freedom of information request with regard to trauma protocols for silver trauma patients. We would like to know the following information if available:
. Does your hospital have a guideline for silver trauma patients (>65 years old) attending ED?
. What are the ED’s indications for initiating a silver trauma call and requesting a trauma CT for elderly patients at your hospital?
· Which specialties are called for silver trauma in ED? Does it include General surgery, Orthopaedics, Anaesthetics and Medicine of the elderly?
· Does your hospital have a guideline for assessing delirium in silver trauma patients (>65 years old)?
· Do all the silver trauma patients get reviewed by medicine of the elderly on the ward if admitted? · Do you have a guideline for assessment of the silver trauma patients on the ward by medicine of the elderly?
· Can you please attach your hospital’s guidelines for silver trauma patients in your reply?
Thank you for your help! Looking forward to your response.
Please do not include any patient confidential information in your response.
Dear FOI Officer, I am writing to request information, under the Freedom of Information Act 2000, regarding carbon monoxide (CO) cases in relation to research for Project SHOUT.
Could you please provide the following information, from the Gloucestershire Health and Care NHS Foundation Trust, for the periods: 1st August 2018 to 31st July 2019:
• The total number of carbon monoxide (CO) cases that attended A&E
1. Of the total figure, how many were aged 0-18 years old 2. Of the total figure, how many were aged 60 years old and over
• The total number of carbon monoxide (CO) cases that were treated at A&E
1. Of the total figure, how many were aged 0-18 years old 2. Of the total figure, how many were aged 60 years old and over 1st August 2019 to 31st July 2020:
• The total number of carbon monoxide (CO) cases that attended A&E
1. Of the total figure, how many were aged 0-18 years old 2.
Of the total figure, how many were aged 60 years old and over
• The total number of carbon monoxide (CO) cases that were treated at A&E
1. Of the total figure, how many were aged 0-18 years old
2. Of the total figure, how many were aged 60 years old and over 1st August 2020 to 31st July 2021:
• The total number of carbon monoxide (CO) cases that attended A&E
1. Of the total figure, how many were aged 0-18 years old
2. Of the total figure, how many were aged 60 years old and over
• The total number of carbon monoxide (CO) cases that were treated at A&E
1. Of the total figure, how many were aged 0-18 years old
2. Of the total figure, how many were aged 60 years old and over 1st August 2021 to 31st July 2022:
• The total number of carbon monoxide (CO) cases that attended A&E
1. Of the total figure, how many were aged 0-18 years old
2. Of the total figure, how many were aged 60 years old and over
• The total number of carbon monoxide (CO) cases that were treated at A&E
1. Of the total figure, how many were aged 0-18 years old
2. Of the total figure, how many were aged 60 years old and over 1st August 2022 to 31st July 2023:
• The total number of carbon monoxide (CO) cases that attended A&E
1. Of the total figure, how many were aged 0-18 years old 2. Of the total figure, how many were aged 60 years old and over
• The total number of carbon monoxide (CO) cases that were treated at A&E
1. Of the total figure, how many were aged 0-18 years old
2. Of the total figure, how many were aged 60 years old and over 1st August 2023 to 31st July 2024:
• The total number of carbon monoxide (CO) cases that attended A&E
1. Of the total figure, how many were aged 0-18 years old
2. Of the total figure, how many were aged 60 years old and over
• The total number of carbon monoxide (CO) cases that were treated at A&E
1. Of the total figure, how many were aged 0-18 years old 2. Of the total figure, how many were aged 60 years old and over 1st August 2024 to 31st July 2025:
• The total number of carbon monoxide (CO) cases that attended A&E
1. Of the total figure, how many were aged 0-18 years old 2. Of the total figure, how many were aged 60 years old and over
• The total number of carbon monoxide (CO) cases that were treated at A&E
1. Of the total figure, how many were aged 0-18 years old 2. Of the total figure, how many were aged 60 years old and over If possible.
I would be grateful to receive this information in an Excel spreadsheet format.
Under the Freedom of Information Act 2000 I would like to request the following information.
This request relates to NHSE’s July 2025 time-series elective care waiting list release from September 2021-June 2025 which disaggregated data by age and sex and partially disaggregated by ethnicity and Indexes of Multiple Deprivation (IMD). Please provide the requested information in an Excel spreadsheet.
1. Share the paediatric elective care waiting list data (under 18) disaggregated by ethnicity and IMD for the time-series September 2021-June 2025, displayed as total numbers waiting month by month. Please indicate if this data has not been collected.
2. Share paediatric community service waiting list data (under 18) disaggregated by ethnicity and IMD for the time-series September 2021– June 2025, displayed as total numbers waiting month by month. If this data has not been collected, please provide the total waiting list for paediatric community care between September 2021-June 2025 by month.
If it is not possible to provide the information requested due to the information exceeding the cost of compliance limits identified in Section 12, please provide advice and assistance, under the Section 16 obligations of the Act, as to how I can refine my request.
If you have any queries, please don’t hesitate to contact me via email and I will be happy to clarify. Thank you for your time and I look forward to your response.
Hi. Thank you for responding to the FOI below. I have a few follow up questions.
1. How many patients have had TMS funded by GHC in the last 24 months.
2. Could you give an estimate on total expenditure on TMS in last 24 months.
3. What providers (NHS or private) have delivered TMS funded by GHC.
I am writing to submit a request for information under the Freedom of Information Act 2000.
I would be grateful if you could provide information regarding your hospitals clinical practice on the timing of methotrexate (MTX) level monitoring in patients receiving high-dose methotrexate (HDMTX) therapy. Specifically, I am seeking the following:
Adult Patients
1. For adult patients with acute lymphoblastic leukaemia (ALL) receiving HDMTX, at what time point does your centre take the first MTX level?
2. For adult patients with osteosarcoma receiving HDMTX, at what time point does your centre take the first MTX level?
3. For adult patients with non-Hodgkin’s lymphoma receiving HDMTX, at what time point does your centre take the first MTX level?
Paediatric Patients
1. For paediatric patients with acute lymphoblastic leukaemia (ALL) receiving HDMTX, at what time point does your centre take the first MTX level?
2. For paediatric patients with osteosarcoma receiving HDMTX, at what time point does your centre take the first MTX level?
3. For paediatric patients with non-Hodgkin’s lymphoma receiving HDMTX, at what time point does your centre take the first MTX level?
Please note that I am not requesting any patient-specific data. This request relates solely to your clinical practice guidelines or standard protocols.
Please can you tell me:
1. The number of patients who have died while on your waiting list to recieve consultant-led elective (planned) hospital treatment — and who have therefore been removed from the list due to to their death or status as being deceased — between January 1 2025 and July 31 2025?
(If your trust calls this particular waiting list something else, please use common sense and provide the waiting list data most relevant to my questions.)
1a. If possible, please tell me how many of these people who died had been waiting for longer than 18 weeks since being referred for consultant-led elective hospital treatment?
1b. If possible, please provide a seperate breakdown of the ethnicity and religion of all those who died while on this your waiting list to recieve consultant-led elective (planned) hospital treatment over this time period.
2. The number of patients who have died while on your waiting list to recieve consultant-led elective (planned) hospital treatment — and who have therefore been removed from the list due to to their death or status as being deceased — broken down into the years 2024, 2023, 2022, 2021 and 2020, please.
2a. If possible, please provide a seperate breakdown of the ethnicity and religion of those who died while on you waiting list for consultant-led elective (planned) hospital treatment in each of these years.
If you are encountering any practical difficulties with complying with this request, please contact me as soon as possible (in line with your duty under section 16 to advise and assist requesters), so that we can discuss the matter and if necessary I can modify the request.
If you are able to supply some of this information more quickly than other items, please supply each item when you can rather than delay everything until it is all available.
Please format this data clearly and provide it in a machine readable format (such as xslx).
I have attached a Freedom of Information request regarding your PROSTHETIC and/or ORTHOTIC services.
Please provide Electro Convulsive Treatment (ECT) information under the FOI act to the following questions: –
1.Please supply patient’s information ECT leaflet
2.Please supply patient ECT consent form
3.Please supply any ECT reports/investigations
4.How many ECT in 2024?
5.What proportion of patients were men/women?
6.How old were they?
7.What proportion of patients were classified people of the global majority or racialised communities (“POC / BAME”)?
8.How many people covered by the equality act – specific protected characteristics – excluding age + gender – received ECT ?
9.How many people were offered talking therapy prior to ECT ?
10.How many were receiving ECT for the first time?
11.How many patients consented to ECT?
12.How many ECT complaints were investigated outside the NHS ?
13.How many patients died during or 1 month after ECT and what was the cause (whether or not ECT was considered the cause)?
14.How many patients died within 6 months after ECT and what was the cause (whether or not ECT was considered the cause)?
15.How many patients died by suicide within 6 months of receiving ECT (whether or not ECT was considered the cause)?
16.How many patients have suffered complications during and after ECT and what were those complications?
17.Have there been any formal complaints from patients/relatives about ECT?
18.If so, what was their concerns?
19.How many patients report memory loss/loss of cognitive function?
20.What tests are used to assess memory loss/loss of cognitive function?
21.Have MRI or CT scans been used before and after ECT?
22.If so, what was the conclusion?
23.How does the Trust plan to prevent ECT in the future?
Please provide restraints information under the FOI act to the following questions: –
1.Please supply any Restraints/investigations
2.How many RESTRAINTS in 2024?
3.What proportion of patients were men/women?
4.How old were they?
5.What proportion of patients were classified people of the global majority or racialised communities (“POC / BAME”)?
6.How many people covered by the equality act – specific protected characteristics – excluding age + gender – were restrainted?
7.How many RESTRAINTS were investigated outside the NHS?
8.How many patients died during or 1 month after RESTRAINTS and what was the cause (whether or not RESTRAINTS was considered the cause)?
9.How many patients died within 6 months after RESTRAINTS and what was the cause (whether or not RESTRAINTS was considered the cause)?
10.How many patients died by suicide within 6 months of receiving RESTRAINTS (whether or not RESTRAINTS was considered the cause)?
11.How many patients have suffered complications during and after RESTRAINTS and what were those complications?
12.Have there been any formal complaints from patients/relatives about RESTRAINTS?
13.If so, what was their concerns?
14.Are counts of forced injections available? if so how many people were forcible injected ?
15.How does the Trust plan to reduce restraints in the future?
16.How many of these restraints were face down restraints?
Please provide SECLUSION information under the FOI act to the following questions: –
1.Please supply any SECLUSION reports/investigations
2.How many SECLUSIONS in 2024?
3.What proportion of patients were men/women?
4.How old were they?
5.What proportion of patients were classified people of the global majority or racialised communities (“POC / BAME”)?
6.How many people covered by the equality act – specific protected characteristics – excluding age + gender – were secluded ?
7.How many SECLUSIONS were investigated outside the NHS?
8.How many patients died during or 1 month after SECLUSION and what was the cause (whether or not SECLUSION was considered the cause)?
9.How many patients died within 6 months after SECLUSION and what was the cause (whether or not SECLUSION was considered the cause)?
10.How many patients died by suicide within 6 months of receiving SECLUSION (whether or not SECLUSION was considered the cause)?
11.How many patients have suffered complications during and after SECLUSION and what were those complications?
12.Have there been any formal complaints from patients/relatives about SECLUSION?
13.If so, what was their concerns?
14.How does the Trust plan to reduce SECLUSIONS in the future?
Please provide MEDICATION ERRORS information under the FOI act to the following questions: –
1.Please supply any MEDICATION ERRORS reports/investigations
2.How many MEDICATION ERRORS in 2024?
3.What proportion of patients were men/women?
4.How old were they?
5.What proportion of patients were classified people of the global majority or racialised communities (“POC / BAME”)?
6.How many people covered by the equality act – specific protected characteristics – excluding age + gender – endured medication errors ?
7.How many MEDICATION ERRORS were investigated outside the NHS ?
8.How many patients died during or 1 month after MEDICATION ERRORS and what was the cause (whether or not MEDICATION ERRORS was considered the cause)?
9.How many patients died within 6 months after MEDICATION ERRORS and what was the cause (whether or not MEDICATION ERRORS was considered the cause)?
10.How many patients died by suicide within 6 months of receiving MEDICATION ERRORS (whether or not MEDICATION ERRORS was considered the cause)?
11.How many patients have suffered complications during and after MEDICATION ERRORS and what were those complications?
12.Have there been any formal complaints from patients/relatives about MEDICATION ERRORS?
13.If so, what was their concerns?
14.How does the Trust plan to prevent MEDICATION ERRORS in the future?
I would like to submit an FOI request for the following data for Gloucestershire Health and Care NHS Foundation Trust:
1. The number of unique patients with a recorded diagnosis of Dravet syndrome in 2024-2025. Likely coded as ICD-10 code G40.3 or SNOMED code of 230437002, ideally separated by month.
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
2. The number of unique patients with a recorded diagnosis of Lennox-Gastaut syndrome in 2024-2025. Likely coded as ICD-10 code G40.4 or SNOMED code of 230418006, ideally separated by month.
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
3. The number of unique patients who have been treated with fenfluramine in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside fenfluramine, and indicate the number of patients receiving each
4. The number of unique patients who have been treated with cannabidiol in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside cannabidiol, and indicate the number of patients receiving each
5. The number of unique patients who have been treated with cenobamate in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside cenobamate, and indicate the number of patients receiving each
6. The number of unique patients who have been treated with rufinamide in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside rufinamide, and indicate the number of patients receiving each
7. The number of unique patients who have been treated with stiripentol in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside stiripentol, and indicate the number of patients receiving each
8. The number of unique patients who have been treated with clobazam in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside clobazam, and indicate the number of patients receiving each
9. The number of unique patients who have been treated with sodium valproate in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside sodium valproate, and indicate the number of patients receiving each
10. The number of unique patients who have been treated with levetiracetam in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside levetiracetam, and indicate the number of patients receiving each
11. The number of unique patients who have been treated with topiramate in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
18 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside topiramate, and indicate the number of patients receiving each
12. The number of unique patients who have been treated with lamotrigine in 2024-2025, separated by month
Patient numbers segmented by age:
0-3 years old
4-8 years old
9-18 years old
8 years+
For these patients, how many of them had a diagnosis of:
Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002
Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006
For these patients, please provide a detailed breakdown of concurrent treatments. Specifically, list each additional treatment received alongside lamotrigine, and indicate the number of patients receiving each
Under the Freedom of Information Act 2000, I would like to request information regarding clinical documentation practices, specifically in relation to the capture of information during interventional procedures, such as Central Venous Access Device (CVAD) insertions.
1. Clinical Documentation
• What methods are currently used by clinicians to document key information during invasive procedures, such as CVAD insertions (e.g., paper forms, digital forms, voice dictation, other)?
o Is any form of structured digital data entry used at the point of care for these procedures?
• Are standardised templates or proformas used Trust-wide for documenting invasive procedures, such as Local Safety Standards for Invasive Procedures (LocSSIPs)?
o Are any of these LocSSIPs or other forms digitised?
2. Voice Technology
• Does the Trust currently use any voice-to-text or voice recognition technology for clinical documentation (e.g., Dragon Medical One, Nuance, Voice-Care, etc.)?
• If yes, which departments or specialties currently use it, and for which types of documentation?
3. Administrative Efficiency
• Has the Trust undertaken any assessments of the administrative time burden associated with completing procedural documentation (manual or digital)?
o If so, is any information available on time spent per procedure or efforts to streamline the process?
4. Future Plans
• Is the Trust currently planning any initiatives or procurements to digitise documentation processes for interventional procedures?
o If yes, please outline the scope and timelines if available.
I am writing under the Freedom of Information Act 2000 to request information relating to the diagnosis and treatment of hip fractures for patients presenting at your Minor Injuries department, broken down by year, for the past four calendar years (2021, 2022, 2023, 2024) up to and including 03 May 2025:
· The number of patients who presented at Minor Injuries with hip pain and were referred for: X-Ray o MRI scan.
· Of those who underwent an X-ray only, how many had negative or inconclusive results but were later diagnosed with a femoral neck or other hip fracture?
If the request exceeds the cost exemption, as per s12 of the 2000 Act, please advise me on how to amend my request accordingly.
I would be grateful if you could please answer the following question with regards to cancer treatment:
In the last 12 months, how many unique patients in your trust have been treated privately for the following ICD-10 codes?
A) C61 Malignant neoplasm of prostate
B) C16.0 Malignant neoplasm of the gastroesophageal Junction
I am writing to request the following information under the Freedom of Information Act:
For the period from January 2019 to the most recent available data, please provide the following details relating to admissions involving the insertion of objects into the anus or vagina.
• The total number of incidents recorded per year.
• The age and gender of the individual involved in each incident (if available and anonymised).
• A brief description of the incident or nature of injury and if the insertion was accidental or deliberate (if available and anonymised).
• The item used – including but not limited to sex toys, household objects, and food.
I am conducting a research project to compare the safety and efficacy of permanent versus absorbable sutures in Colposuspension for the management of stress urinary incontinence in women. I would be grateful if you could help me with this data.
From your hospital surgical database, please can you provide us with:
1. the number of Colposuspensions conducted in your unit between January 2020 and January 2025.
Of these, please clarify how many were conducted:
-open
-laparoscopically
-robotically
2. How many of these cases have needed to go back to theatre for any procedure under the care of urogynaecology/gynaecology/urology since the initial operation?
Please state, what procedures they then underwent.
The following questions, may be known by the theatre team via the surgeon’s cardex (information sheet which each surgeon will have with their preference of equipment for each operation) for Colposuspension. In the worst case, it may need to posed to the surgeons who usually perform colposuspensions but should be a quick answer:
“Which suture material is routinely used to suture onto the iliopectineal ligament in open cases? Please state name of suture or N/A if this route of colposuspension is not performed.”
“Which suture material is routinely used to suture onto the iliopectineal ligament in laparoscopic cases? Please state name of suture or N/A if this route of colposuspension is not performed.”
“Which suture material is routinely used to suture onto the iliopectineal ligament in robotic cases? Please state name of suture or N/A if this route of colposuspension is not performed.”
1. Does your trust have an AKI lead? (Yes/No)
2. Do you use an AKI bundle for patient care within your trust? (Yes/ No)
– If so what care bundle do you use?
3. Are you a paperless trust? (Yes/No)
4. What electronic system do you use for electronic noting?
5. Is your electronic noting system used for all healthcare professions within the organisation? (Yes/No)
6. Do you have AKI nurses within your trust? (Yes/No)
-If so- how many? Are they clinical nurse specialists, advanced practitioners, or another role title?
-Does their role banding meet national standards (Qualified Advanced Clinical Practitioners 8a, Trainee Advanced Clinical Practitioners- band 7, Lead Clinical Nurse Specialists – band 7,Clinical Nurse Specialist- band 6)? (Yes/No)
7. Does your trust have a renal unit? (Yes/No)
8. How many adult inpatient beds does your trust have?
Please can you advise the total number of patients that have been referred to the Heart Failure Diagnostics Clinic within your trust for the following years: 2022, 2023, 2024
1. In the past three years, how many patients aged 65 and above attended/were admitted to a hospital apart of the trust with health problems related to cold temperatures, such as chest infections, respiratory conditions, flu, hypothermia and others? (Broken down by years: 2022, 2023, 2024)
2. How many excess winter deaths (EWDs) have the trust recorded in the past three years? (Broken down by years: 2022, 2023, 2024)
3. Of these deaths, how many were aged 65 and above? (Broken down by years: 2022, 2023, 2024)
Q1 Trust Name:
Q2 Type of Healthcare Facilities
o District General Hospital (DGH) (1)
o Specialty Hospital (2)
o Private Hospital (3)
o Community Hospital (4)
o Other (Please Specify) (5)
Q3 Demographic of Hospital Care
o Adult Hospital (1)
o Paediatric Hospital (2)
o General Hospital (Both paediatric and adult) (3)
o GP surgery (4)
o Other (Please Specify) (5)
Q4 Respondent’s Role in the Trust:
o Medical Records Manager (1)
o IT Specialist (2)
o Clinician (3)
o Administrator (4)
o Other (Please Specify) (5)
Q5 Does your Trust use electronic patient records (EPR)?
o Yes (1)
o No (2)
Q6 Which EPR system does your Trust use?
▢ Cerner (1)
▢ Epic (2)
▢ System C (3)
▢ Dedalus (4)
▢ Altera (5)
▢ Other (Please Specify (6)
Q7 Does the EPR system used by your Trust include a specific section for recording food, drug, latex, and other allergies?
o Yes (1)
o No (2)
Q8 If yes to question 7, how is the initial allergy information typically entered into the system? (Select all that relevant)
▢ Manually by Doctor (1)
▢ Manually by Pharmacist (5)
▢ Manually by Nurse (6)
▢ Manually by Dietitian (7)
▢ Automatically from Previous Records (2)
▢ Manually by Administrative Staff (3)
▢ Other (Please Specify) (4)
Q9 If yes to question 7, who is responsible for updating and/or checking allergy information in the patient’s electronic record? (Select all that apply)
▢ Clinicians (e.g., doctors, nurses) (1)
▢ Administrative Staff (2)
▢ Pharmacists (3)
▢ IT/Technical Support Staff (4)
▢ Don’t Know (5)
▢ Other (Please Specify) (6)
Q10 How is the allergy information flagged or highlighted in the patient’s records to alert healthcare providers?
o Red Flag (1)
o Pop-up Alert (2)
o Highlighted Text (3)
o Other (Please Specify) (4)
o Not highlighted/ alerted on the system (5)
Q11 What training, if any, is provided to staff on the correct recording of allergies in patient records?
o Mandatory Training Sessions (1)
o Optional Training (2)
o No Training Provided (3)
o Other (Please Specify) (4)
Q12 If training is provided on allergy documentation, does it specifically cover different types of allergies in the training materials?
o Only drug allergy recording (1)
o Both drug and non-drug allergy recording (2)
o Drug, food, and other non-drug allergy recording (e.g., latex) (3)
o Don’t know/ Unsure (4)
Q13 Does your Trust have a Local Guideline or Standard Operating Procedure (SOP) in place covering allergy documentation on the EPR?
o Yes (3)
o No (5)
o Don’t know/ Unsure (4)
Q14 If yes to Question 13, does this guideline/SOP include documentation for allergens below? (Select all that relevant)
▢ Drugs (1)
▢ Food (2)
▢ Other non-drug substances (e.g. latex) (3)
▢ Don’t know/ Unsure (5)
Q15 Does your hospital have access to specialist allergy advice for paediatric patients?
o Yes, please specify if this service available is available through In-House, Local Centre or Regional Centre. (1)
o No (2)
Q16 Does your hospital have access to specialist allergy advice for adult patients?
o Yes, please specify if this service available is available through In-House, Local Centre or Regional Centre. (1)
o No (2)
Q17 Does the incident reporting platform have a specific category for recording food or other non-drug allergy incidents?
o Yes (1)
o No (2)
Q18 In the last 10 years, has your Trust recorded any incidents where a patient was administered a food, drug, or other substance (e.g., latex) they were known to be allergic to?
o Yes (1)
o No (2)
Q19 If yes to question 18, how many such incidents have been reported in the last 10 years? [Numerical Response]
o <5, please specify (1)
o 5 – 9, please specify (2)
o 10 – 19, please specify (3)
o ≥ 20, please specify (4)
o Don’t know (5)
Q20 If yes to question 18, please indicate the number of incidents for each category: [Numerical Response]
▢ Drug allergy incidents (1)
▢ Food allergy incidents (2)
▢ Incidents to other allergic substances (3)
▢ Don’t know/ unaware (4)
Q21 Considering the start date of your EPR system, how many years’ worth of incident data have you been able to search for this survey? Ideally, up to 10 years. (e.g. 2014 – 2024)
Q22 For reported DRUG ALLERGY incidents, what are the drugs involved, age group (≤17 or >17 years), and level of harm (no harm, low harm, moderate harm, severe harm or death), listing up to 10 cases prioritized by severity of harm, followed by the most recent incidents?
Please indicate the total cases below if more than 10 cases were reported.
Example: Case 1 (Amoxicillin, >17yo, low harm).
▢ Case 1 (allergen, age, level of harm) (1)
▢ Case 2 (allergen, age, level of harm) (2)
▢ Case 3 (allergen, age, level of harm) (3)
▢ Case 4 (allergen, age, level of harm) (4)
▢ Case 5 (allergen, age, level of harm) (5)
▢ Case 6 (allergen, age, level of harm) (7)
▢ Case 7 (allergen, age, level of harm) (8)
▢ Case 8 (allergen, age, level of harm) (9)
▢ Case 9 (allergen, age, level of harm) (10)
▢ Case 10 (allergen, age, level of harm) (11)
▢ If more than 10 cases are reported, please indicate the total number of cases below. (13)
▢ No drug allergy incidents reported (14)
Q23 For reported FOOD and OTHER NON-DRUG ALLERGY incidents, what are the allergens involved, age (confirm age via clinical record if required), reactions, if serious incident reported and level of harm (no harm, low harm, moderate harm, severe harm or death), listing up to 10 cases prioritized by severity of harm, followed by the most recent incidents?
Please indicate the total cases below if more than 10 cases were reported.
Example: Case 1 (Peanut, 3yo, anaphylaxis, serious incident reported, moderate harm).
▢ Case 1 (allergen, age, reaction, serious incident reported, level of harm) (1)
▢ Case 2 (allergen, age, reaction, serious incident reported, level of harm) (2)
▢ Case 3 (allergen, age, reaction, serious incident reported, level of harm) (3)
▢ Case 4 (allergen, age, reaction, serious incident reported, level of harm) (4)
▢ Case 5 (allergen, age, reaction, serious incident reported, level of harm) (5)
▢ Case 6 (allergen, age, reaction, serious incident reported, level of harm) (7)
▢ Case 7 (allergen, age, reaction, serious incident reported, level of harm) (8)
▢ Case 8 (allergen, age, reaction, serious incident reported, level of harm) (9)
▢ Case 9 (allergen, age, reaction, serious incident reported, level of harm) (10)
▢ Case 10 (allergen, age, reaction, serious incident reported, level of harm) (11)
▢ If more than 10 cases report, please indicate the total number of cases below. (13)
▢ No food allergy OR other non-drug allergy incidents reported (14)
Q24 For FOOD AND OTHER NON-DRUG ALLERGY incidents, how many of the incidents was the allergen clearly documented in patients notes/correspondence prior to the incident? Please insert the number of cases involved in each category. (e.g. 0 – 100)
▢ Food allergies documented correctly, please specify: (1)
▢ Food allergies not documented, please specify: (2)
▢ Non-drug allergies documented correctly, please specify: (3)
▢ Non-drug allergies not documented, please specify: (4)
▢ The food/ non-drug allergens were not previously known (7)
Q25 For FOOD AND OTHER NON-DRUG ALLERGY incidents, how many of the incidents was the allergen correctly documented on the relevant field in EPR prior to incident (Cerner / Epic / Other)? Please insert the number of cases involved in each category. (e.g. 0 – 100)
▢ Food allergies documented correctly, please specify: (1)
▢ Food allergies not documented, please specify: (2)
▢ Non-drug allergies documented correctly, please specify: (3)
▢ Non-drug allergies not documented, please specify: (4)
▢ The food/ non-drug allergens were not previously known (5)
Q26 What were the causes identified in the food or other non-drug incidents? (Multiple answers allowed)
▢ Allergy not recorded in EPR (1)
▢ Allergy recorded but not flagged/alerted (2)
▢ Staff did not check EPR (3)
▢ Incorrect substance administered due to similar names/packaging (4)
▢ System error or failure (5)
▢ Other (Please Specify) (6)
▢ Unsure/ Don’t know (7)
Q27 What challenges, if any, does your Trust face in accurately recording and managing allergy information in EPR systems?
Q28 What improvements do you suggest could be made at a national level to better manage allergy information in patient records?
1. Please can you list the sites/locations that your Trust conducts elective surgery?
2. We are keen to understand whether your Trust are using any elective hubs – defined as exclusively performing planned surgery with ring fenced facilities and staff. Does your Trust use such a facility? If so, please list out the locations?
3. Are any of the elective hubs that you use managed by a different Trust?
4. Please could you list any Community Diagnostic Centres that your Trust makes use of that are located away from your acute hospital sites?
Is FERN still operational and comprised of the same team members?
If yes, is this not counter to NHS England’s position statement that police should not be involved in care?
If no, what has replaced it and how has police involvement in care been “eradicated” as mandated by NHS England?
1. Tetrabenazine usage. I am trying to determine the disease areas for the usage of Tetrabenazine.
Therefore, where possible to split the usage between the following disease areas:
Huntington’s Disease
Tardive Dyskinesia
Parkinson’s disease
Medication induced Dystonia
2. I am also trying to define the treatment sites for mental health provision within both the hospital and community settings, e.g.
All available treatment pathways for patients with eating disorders in the Trust’s various specialist services (e.g. inpatient / day patient / community)?
The number of eating disorder patients in total on each available pathway and in each available setting so far this year and in each of the past 5 years.
The number of patients in total with an eating disorder that have died of any cause so far this year and in each of the past 5 years.
Of the patients in question three, above, please provide the location in which the death occurred, for example, in an acute hospital, in the Specialist Eating Disorder Unit, in a palliative care setting, elsewhere in the Trust, or outside any Trust setting.
Please provide a copy of your Trust’s SEED (Severe and Enduring Eating disorder) pathway or similar pathway for patients with long-standing eating disorders.
How many patients have been treated through the Gloucestershire Health and Care NHS Foundation Trust’s post-COVID service, and what ethnic groups are they a part of? Please can you break down the numbers year by year since the service started to the present day.
How many patients remained on the waiting list each month for the service, and what ethnic groups are they a part of? Please can you break down the numbers year by year since the service started to the present day.
How many staff have been designated to your post-COVID service each year since the service started to the present day?
Please provide Electro Convulsive Treatment (ECT) information under the FOI act to the following questions: –
1.Please supply patient’s information ECT leaflet
2.Please supply patient ECT consent form
3.Please supply any ECT reports/investigations
4.How many ECT in 2023?
5.What proportion of patients were men/women?
6.How old were they?
7.What proportion of patients were classified people of the global majority or racialised communities (“POC / BAME”)?
8.How many people covered by the equality act received ECT ?
9.How many people were offered talking therapy prior to ECT ?
10.How many were receiving ECT for the first time?
11.How many patients consented to ECT?
12.How many ECT complaints were investigated outside the NHS and CCG?
13.How many patients died during or 1 month after ECT and what was the cause (whether or not ECT was considered the cause)?
14.How many patients died within 6 months after ECT and what was the cause (whether or not ECT was considered the cause)?
15.How many patients died by suicide within 6 months of receiving ECT (whether or not ECT was considered the cause)?
16.How many patients have suffered complications during and after ECT and what were those complications?
17.Have there been any formal complaints from patients/relatives about ECT?
18.If so, what was their concerns?
19.How many patients report memory loss/loss of cognitive function?
20.What tests are used to assess memory loss/loss of cognitive function?
21.Have MRI or CT scans been used before and after ECT?
22.If so, what was the conclusion?
23.How does the Trust plan to prevent ECT in the future?
Please provide restraints information under the FOI act to the following questions: –
1.Please supply any Restraints/investigations
2.How many RESTRAINTS in 2023?
3.What proportion of patients were men/women?
4.How old were they?
5.What proportion of patients were classified people of the global majority or racialised communities (“POC / BAME”)?
6.How many people covered by the equality act were restrained?
7.How many RESTRAINTS were investigated outside the NHS and CCG?
8.How many patients died during or 1 month after RESTRAINTS and what was the cause (whether or not RESTRAINTS was considered the cause)?
9.How many patients died within 6 months after RESTRAINTS and what was the cause (whether or not RESTRAINTS was considered the cause)?
10.How many patients died by suicide within 6 months of receiving RESTRAINTS (whether or not RESTRAINTS was considered the cause)?
11.How many patients have suffered complications during and after RESTRAINTS and what were those complications?
12.Have there been any formal complaints from patients/relatives about RESTRAINTS?
13.If so, what was their concerns?
14.Are counts of forced injections available?
15.How does the Trust plan to reduce restraints in the future?
Please provide SECLUSION information under the FOI act to the following questions: –
1.Please supply any SECLUSION reports/investigations
2.How many SECLUSIONS in 2023?
3.What proportion of patients were men/women?
4.How old were they?
5.What proportion of patients were classified people of the global majority or racialised communities (“POC / BAME”)?
6.How many people covered by the Equality Act were secluded ?
7.How many SECLUSIONS were investigated outside the NHS and CCG?
8.How many patients died during or 1 month after SECLUSION and what was the cause (whether or not SECLUSION was considered the cause)?
9.How many patients died within 6 months after SECLUSION and what was the cause (whether or not SECLUSION was considered the cause)?
10.How many patients died by suicide within 6 months of receiving SECLUSION (whether or not SECLUSION was considered the cause)?
11.How many patients have suffered complications during and after SECLUSION and what were those complications?
12.Have there been any formal complaints from patients/relatives about SECLUSION?
13.If so, what was their concerns?
14.How does the Trust plan to reduce SECLUSIONS in the future?
Please provide MEDICATION ERRORS information under the FOI act to the following questions: –
1.Please supply any MEDICATION ERRORS reports/investigations
2.How many MEDICATION ERRORS in 2023?
3.What proportion of patients were men/women?
4.How old were they?
5.What proportion of patients were classified people of the global majority or racialised communities (“POC / BAME”)?
6.How many people covered by the equality act endured medication errors ?
7.How many MEDICATION ERRORS were investigated outside the NHS and CCG?
8.How many patients died during or 1 month after MEDICATION ERRORS and what was the cause (whether or not MEDICATION ERRORS was considered the cause)?
9.How many patients died within 6 months after MEDICATION ERRORS and what was the cause (whether or not MEDICATION ERRORS was considered the cause)?
10.How many patients died by suicide within 6 months of receiving MEDICATION ERRORS (whether or not MEDICATION ERRORS was considered the cause)?
11.How many patients have suffered complications during and after MEDICATION ERRORS and what were those complications?
12.Have there been any formal complaints from patients/relatives about MEDICATION ERRORS?
13.If so, what was their concerns?
14.How does the Trust plan to prevent MEDICATION ERRORS in the future?
SECTION 1: Hospital Demographics
1. Please indicate your trust/hospital type and type of care:
1. Trust/Hospital Type:
i) Acute
ii) Mental Health
iii) Community
iv) Ambulance
v) Other (please specify)
2. Type of Care:
i) Secondary
ii) Tertiary
iii) Other (please specify)
3. Total Number of Beds: Please indicate the total number of inpatient beds in your hospital, including all types (e.g., general, ICU, maternity) if applicable.
4. ICU/ITU Bed Count: How many beds are designated for intensive or high-dependency care?
5. Annual Admissions: Please provide the total number of patient admissions in the last calendar year. If exact figures are unavailable, please provide your best estimate.
SECTION 2: Procurement and Inventory Management
1. Formal Procurement Policies: Does your hospital have formal policies or guidelines for medical equipment procurement?
i) Yes (please provide a copy or summary)
ii) No
2. Designated Procurement Roles: Is there a designated individual or team responsible for managing the procurement of medical equipment? If yes, please provide the role(s) and a brief description of responsibilities.
i) Yes – Individual
ii) Yes – Team
iii) No
3. Inventory Review Frequency: How often is your medical equipment inventory reviewed for excess or unused items?
i) Monthly
ii) Quarterly
iii) Biannually
iv) Annually
v) Other (please specify)
4. Primary Sources for Procurement:
What are the primary sources for your medical equipment procurement?
Please indicate the proportion sourced from the NHS supply chain versus individual suppliers, and provide any additional details as applicable.
SECTION 3: Waste and Disposal
1. Excess/Expired Equipment:
What percentage of your medical equipment inventory was classified as excess, unused, or expired in the last 12 months?
Please provide a breakdown by equipment type, if available.
2. Disposal Responsibility: Is there a specific role or department responsible for overseeing the disposal of medical equipment? If yes, please provide the role(s) and responsibilities.
i) Yes – Individual
ii) Yes – Department
iii) No
3. Formal Disposal Policy: Does your hospital have a formal policy for the disposal of medical equipment?
i) Yes (please provide a copy or summary of any policies)
ii) No
4. Types of Commonly Disposed Equipment: Please specify the types of medical equipment most commonly disposed of due to expiry or non-use. Include examples and approximate percentages for each type, if possible.
i) Surgical instruments
ii) Diagnostic devices
iii) Monitoring equipment
iv) Imaging equipment
v) Other (please specify)
SECTION 4: Sustainability and Environmental Impact
1. Sustainability Initiatives: Does your hospital have a sustainability initiative for recycling, reuse, or redistribution of excess or unused medical equipment?
i) Yes (please provide details)
ii) No
2. Disposal of Excess or Expired Equipment: How does your hospital manage the disposal of excess, expired, or damaged equipment? Please provide a breakdown by disposal method and indicate the approximate amount (in tonnes) used per year for each method.
i) Recycling
ii) Donation
iii) General waste
iv) Other (please specify)
SECTION 5: Policies and Compliance
1. Compliance with Disposal Guidelines: How does your hospital ensure compliance with national or NHS guidelines on the disposal and management of medical equipment?
i) Internal audits
ii) External audits
iii) Regular staff training
iv) Other (please specify)
2. Internal Audits of Equipment Management: Has your hospital conducted internal audits within the last 12 months to assess the management of excess medical equipment?
i) Yes (If yes, please indicate the frequency of audits and any key findings, if available)
ii) No
Please could you give us current information in relation to how prostate cancer patients are managed when they are eligible for active surveillance/monitoring. Including:
Inclusion criteria
Diagnosis and treatment decision support
Follow-up pathways and protocols
Follow-up testing frequencies
Triggers for stopping active surveillance
In an Excel spreadsheet with information for Q 6 – 21 broken down by each pathology provider in your trust
1. What is the size of your trust’s serviceable population?
2. How many patients has the trust tested for the following clinical biochemical markers in the last 12 months?
a. C-reactive protein (CRP)
b. High-sensitivity C-reactive protein (hs-CRP)
c. Lipoprotein-a (Lp(a))
3. Is there a limit to the frequency of the following tests per patient?
a. C-reactive protein (CRP)
b. High-sensitivity C-reactive protein (hs-CRP)
c. Lipoprotein-a (Lp(a))
4. Please provide the name and post code of all the pathology providers in your trust
5. Do you outsource any testing to commercial labs? If yes, please provide the names of each commercial provider
Please answer the following questions for each pathology provider in your trust
6. Does the laboratory currently offer testing for the following?
a. C-reactive protein (CRP)
b. High-sensitivity C-reactive protein (hs-CRP)
c. Lipoprotein-a (Lp(a))
7. What is the average turnaround time for an outpatient from blood sample collection to sharing of results for CRP and hs-CRP?
8. Is CRP offered as a standalone test or part of a panel?
9. Is hs-CRP offered as a standalone test or part of a panel?
10. What machines are used to conduct CRP testing in your laboratory?
11. What machines are used to conduct hs-CRP testing in your laboratory?
12. What is the lowest limit of detection (in mg/L) that you report for CRP?
13. What is the lowest limit of detection (in mg/L) that you report for hs-CRP?
14. How many requests for measurement of CRP did your laboratory complete in the last 12 months?
15. How many requests for measurement of hs-CRP did your laboratory complete in the last 12 months?
16. What is the maximum number of CRP tests that your laboratory can conduct in one month?
17. What is the maximum number of hs-CRP tests that laboratory can conduct in one month?
18. What is the cost of running a single CRP test in your laboratory? Please provide a breakdown of cost of running the test and all-in cost considering operations, FTEs etc.
19. What is the cost of running a single hs-CRP test in your laboratory? Please provide a breakdown of cost of running the test and all-in cost considering operations, FTEs etc.
20. How much are you reimbursed for a single CRP test in your laboratory?
21. How much are you reimbursed for a single hs-CRP test in your laboratory?
1. Does Gloucestershire Health and Care NHS Foundation Trust use single use endoscopes for any of its endoscopy procedures?
a. If so, can you state in which procedures they are used?
b. If so, can you state which brand/s of endoscopes are used?
2. Can Gloucestershire Health and Care NHS Foundation Trust state how many single use endoscopes have been used in 2021, 2022, 2023 and 2024?
3. Can Gloucestershire Health and Care NHS Foundation Trust state how many single use endoscopes are planned to be used in 2024, 2025, and 2026.
4. Does Gloucestershire Health and Care NHS Foundation Trust have plans to increase the use of single use endoscopes to help in the delivery of Community Diagnostic Centres and temporary out-of-hours hubs to reduce waiting lists?
1. How many Long Covid Clinics for Adults are there within your Trust?
2. How many Long Covid Clinics for Children are there within your Trust?
3. Can you list each Long Covid Clinic for Adults within your Trust?
4. Can you list each Long Covid Clinic for Children within your Trust?
5. If you have no Long Covid Clinics for Adults within your Trust, what services do you provide for Adults?
6. If you have no Long Covid Clinics for Children within your Trust, what services do you provide for Children?
1. How is waitlist validation carried out in your Trusts? Please select one of the following options: Manually / Semi-automated / Automated.
a. If your response was semi-automated or automated, which tools do you use? Please specify the types of tools or software used.
2. How many FTEs currently work on waitlist validation and what band are they? Please specify the number per band.
3. How has your FTE count working on waitlist validation increased in the past 2-3 years? Please provide an estimate if you do not have the exact number.
4. In the past 12 months, approximately how long has the waitlist validation process taken? Please provide an estimate if you do not have the exact number.
5. What data quality issues have been identified the most frequently as part of the waitlist validation process? Please select those that apply from the list below:
a. Decision to admit but no waiting list entry
b. Missing waiting list or pathway information (e.g. due date, intended procedure)
c. Patients on an admitted waiting list without an active RTT (Referral to Treatment Pathway) clock
d. Past TCI (To Come In) dates
e. Potential duplicates
f. Other – please specify
6. What are your current approaches to linking data? Please select one of the following options: Manually or semi-automated / Automated
7. What is the proportion of data linkage that is manual and automated? Please provide an estimate if you do not have the exact number.
a. If automated, what tools are used? Please provide the name of the tools.
b. If manual, what tools are used e.g. R, data bricks? Please provide the name of the tools.
8. Currently, is the data linking process cumbersome? Please select one option: Yes/No
9. And does it take away from people’s everyday role? Please select one option: Yes/No